Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring childhood infratentorial ependymoma, childhood supratentorial ependymoma, adult medulloblastoma, adult myxopapillary ependymoma, adult anaplastic ependymoma, adult ependymoblastoma, untreated childhood supratentorial primitive neuroectodermal tumor, untreated childhood medulloblastoma, newly diagnosed childhood ependymoma, adult supratentorial primitive neuroectodermal tumor (PNET)
Eligibility Criteria
DISEASE CHARACTERISTICS: Histological confirmation of one of the following: High stage medulloblastoma with neuraxis dissemination (Chang stage M1 or greater) Primitive neuroectodermal tumor Ependymoma Incompletely resected on postoperative MRI or neurosurgical report Definitive prior surgery within 42 days of study PATIENT CHARACTERISTICS: Age: 10 to 65 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 mg/dL SGPT less than 2.5 times upper limit of normal Renal: Creatinine clearance greater than 60 mL/min PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Prior corticosteroids allowed No concurrent corticosteroids as antiemetics Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics
Sites / Locations
- Children's Hospital Los Angeles
- Geisinger Medical Center
- Tom Baker Cancer Centre - Calgary